08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Boehringer Ingelheim, WellPoint deal

Boehringer and WellPoint’s HealthCore Inc. unit have identified non-valvular atrial fibrillation (NVAF) as the first project under their July deal to collaborate on the collection of real world health economic and outcomes data. HealthCore, which...
08:00 , Nov 24, 2014 |  BioCentury  |  Product Development

LDL Does IMPROVE IT

The long-awaited results from the IMPROVE-IT cardiovascular outcomes trial have been hailed as opening the gates for next-generation cholesterol drugs to gain approval on the basis of LDL reductions alone. That may be true. But...
02:24 , Nov 22, 2014 |  BC Extra  |  Company News

Boehringer, WellPoint studying outcomes in AF

Boehringer Ingelheim GmbH (Ingelheim, Germany) and the HealthCore Inc. unit of WellPoint Inc. (NYSE:WLP) have identified non-valvular atrial fibrillation (NVAF) as the first project under their July deal to collaborate on the collection of real...
07:00 , Sep 15, 2014 |  BioCentury  |  Strategy

Cancer: Cost and quality

Early data from the first of several U.S. experiments with cancer payment reform offer the tantalizing possibility that drug companies could actually benefit from schemes designed to reward oncologists for outcomes as well as cost...
07:00 , Sep 8, 2014 |  BioCentury  |  Product Development

Betting big on hearts

Though saturation by cheap generics and a high-profile failure of another compound led some companies to exit the heart failure space, results from the PARADIGM-HF trial suggest Novartis AG made the right call by doubling...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

WellPoint cancer news

WellPoint is launching a new program that will reward oncologists who follow recommended treatment regimens, which the payer said could save about $220 million annually once fully implemented. The Cancer Care Quality Program will initially...
07:00 , Jun 2, 2014 |  BioCentury  |  Strategy

Reforming oncology

The American Society of Clinical Oncology has made drug prices and value a centerpiece of its annual meeting this week, but its newly unveiled payment model doesn't yet address how physician practices actually should be...
07:00 , Jun 2, 2014 |  BioCentury  |  Strategy

PrEPping for Truvada

CDC 's recommendation of Truvada for HIV pre-exposure prophylaxis is unlikely to trigger an explosion in prescriptions for the drug, despite estimates that as many as half a million people could be candidates in the...
01:03 , May 29, 2014 |  BC Extra  |  Top Story

WellPoint pilots cancer quality program

WellPoint Inc. (NYSE:WLP) announced its new Cancer Care Quality Program that will reward oncologists for following recommended treatment regimens. The program will initially focus on breast, lung and colorectal cancers and defines specific drug regimens...
02:18 , Jan 30, 2014 |  BC Extra  |  Politics & Policy

WellPoint: exchanges meet company's expectations

Health insurer WellPoint Inc. (NYSE:WLP) said during a conference call on Wednesday to discuss its 4Q13 earnings that it had received about 400,000 health insurance applications through state and federal health exchanges in 2013, plus...